Results 221 to 230 of about 141,380 (258)
Some of the next articles are maybe not open access.
American Journal of Therapeutics, 2010
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality.
Jaya Prakash, Sugunaraj +4 more
openaire +2 more sources
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality.
Jaya Prakash, Sugunaraj +4 more
openaire +2 more sources
Clopidogrel-Associated Leukopenia
The Annals of Pharmacotherapy, 2003OBJECTIVE: To report a case of leukopenia in a patient receiving clopidogrel following intracoronary stent placement. CASE SUMMARY: A 58-year-old white man presented to the emergency department (ED) with fever and chills. Seven days prior to presentation, he underwent intracoronary stent placement and clopidogrel 75 mg once daily was initiated.
Michelle W. McCarthy, Denise R Kockler
openaire +2 more sources
Clopidogrel for Cerebrovascular Prevention
Cerebrovascular Diseases, 1999Ischemic stroke, myocardial infarction and peripheral arterial disease are different clinical manifestations commonly due to the same underlying disease, i.e. atherosclerosis with subsequent thrombosis/embolism (atherothrombosis). Many clinical trials of secondary prevention after stroke or TIA have evaluated the benefit of long-term use of ...
Paciaroni M, Bogousslavsky J
openaire +4 more sources
Clopidogrel and Postoperative Bleeding
The Annals of Thoracic Surgery, 2004lopidogrel, also known as Plavix, is an inhibitor ofadenosine diphosphate–induced platelet aggrega-tion (thienopyridine derivate). In combination with aspi-rin, which blocks the thromboxane-mediated pathway, itis recommended as the standard therapy for preventionof coronary artery stent thrombosis [1].
Piet W. Boonstra, Wim van Oeveren
openaire +3 more sources
American Journal of Cardiovascular Drugs, 2012
Dual antiplatelet therapy with acetylsalicylic acid (aspirin) and clopidogrel is a guideline-recommended standard of care for patients with acute coronary syndromes (ACS) and those who undergo percutaneous coronary intervention (PCI). Despite a large body of clinical evidence obtained from randomized clinical trials and patient registries supporting ...
Saihari Sadanandan, Inder M. Singh
openaire +2 more sources
Dual antiplatelet therapy with acetylsalicylic acid (aspirin) and clopidogrel is a guideline-recommended standard of care for patients with acute coronary syndromes (ACS) and those who undergo percutaneous coronary intervention (PCI). Despite a large body of clinical evidence obtained from randomized clinical trials and patient registries supporting ...
Saihari Sadanandan, Inder M. Singh
openaire +2 more sources
The Journal of Pediatrics, 2005
Abstract Background: Children with congenital heart problems have an increased incidence (up to 4%) of thrombotic vascular complications, particularly after interventional catheterization procedures that include device implantation. Clopidogrel, a thienopyridine derivative, is a specific platelet aggregation inhibitor. The preferred anti-
Yaron Finkelstein +4 more
openaire +4 more sources
Abstract Background: Children with congenital heart problems have an increased incidence (up to 4%) of thrombotic vascular complications, particularly after interventional catheterization procedures that include device implantation. Clopidogrel, a thienopyridine derivative, is a specific platelet aggregation inhibitor. The preferred anti-
Yaron Finkelstein +4 more
openaire +4 more sources
Interaction of Clopidogrel and Omeprazole
New England Journal of Medicine, 2010To the Editor: The label for clopidogrel warns physicians to “avoid concomitant use of . . . strong or moderate CYP2C19 inhibitors.” Such inhibitors (e.g., omeprazole) decrease the formation of the active metabolite of clopidogrel, the source of its antiplatelet effects.
Robert Temple, Mary Ross Southworth
openaire +2 more sources
Smoking, atherothrombosis and clopidogrel
Heart, 2012Smoking is well understood to increase the risk of atherothrombotic events by some two to threefold.1–3 Putting it another way, in 2003 the SCORE project estimated that over a period of 10 years smokers compared with non-smokers have approximately twice the risk of a fatal cardiovascular event.4 Set against this elevation in risk, it was reported in ...
Mark J. Paul-Clark +2 more
openaire +3 more sources
Pharmacogenomics of Clopidogrel
2014In "Handbook of Pharmacogenomics and stratified medicine" (edited by Sandosh Padmanabhan of the University of Glasgow, UK), the Chapter 25 "Pharmacogenomics of clopidogrel" (by Betti Giusti, Claudia Saracini, Silvia Galora, Rossella Marcucci) addresses the state of the art for this issue.
GIUSTI, BETTI +3 more
openaire +2 more sources